Skip to main content
SpringerLink
Log in

Prostatakarzinom: palliative Therapie

Die Urologie

Part of the book series: Springer Reference Medizin ((SRM))

Zusammenfassung

Ist eine kurative Therapie aufgrund des lokal fortgeschrittenen oder metastasierten Primärbefundes nicht mehr möglich oder wünscht der Patient bei lokal begrenzter Erkrankung keine kurative Behandlungsoption, kommen palliative Therapiekonzepte zum Tragen. Aufgrund des häufig langsamen Erkrankungsverlaufs kann diese palliative Phase beim Prostatakarzinom viele Jahre umfassen. Bei relevanten Begleiterkrankungen begrenzen häufig konkurrierende Todesursachen die Lebenserwartung. Die Hormontherapie stellt den Standard der palliativen Therapie dar. Im kastrationsresistenten Stadium haben sich in den letzten Jahren neben der Chemotherapie eine Vielzahl neuer Substanzen etabliert, für die eine gute Symptomkontrolle sowie eine Verbesserung des medianen Gesamtüberlebens nachgewiesen werden konnte. Neben neuen Ansätzen zur Hormonmanipulation erweitern auch immunologische und nuklearmedizinische Ansätze das therapeutische Spektrum. Ergänzende Supportivmaßnahmen und eine angepasste Schmerztherapie haben während der gesamten Erkrankungsdauer einen sehr hohen Stellenwert. Vor allem zur Behandlung von symptomatischen Metastasen kommt hierbei der Strahlentherapie eine wichtige Rolle zu.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Abrahamsson PA (2010) Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 57:49–59

    Article  CAS  PubMed  Google Scholar 

  • Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29:1335–1341

    Article  PubMed Central  PubMed  Google Scholar 

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) PREVAIL Investigators Enzalutamid in metastatic prostate cancer before chemotherapy. New Engl J Med 371:424–433

    Article  PubMed Central  PubMed  Google Scholar 

  • Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  CAS  PubMed  Google Scholar 

  • Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257–2264

    Article  CAS  PubMed  Google Scholar 

  • Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423–1436

    Article  PubMed  Google Scholar 

  • Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE (2011) A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 186:889–897

    Article  CAS  PubMed  Google Scholar 

  • Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28:788–798

    Google Scholar 

  • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  • Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, COU-AA-301 Investigators (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992

    Article  CAS  PubMed  Google Scholar 

  • Friedlander JI, Duty BD, Okeke Z, Smith AD (2012) Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies. J Endourol 26:102–109

    Article  PubMed  Google Scholar 

  • Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J, SPCG-5 Study Group (2008) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 42:220–229

    Article  CAS  PubMed  Google Scholar 

  • Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24:3984–3990

    Article  PubMed  Google Scholar 

  • Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314–1325

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kantoff PW, Mohler JL (2013) New developments in the management of prostate cancer. J Natl Compr Canc Netw 11:653–657

    CAS  PubMed  Google Scholar 

  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  CAS  PubMed  Google Scholar 

  • Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H, PROSTY study Group (2013) 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14:117–124

    Article  CAS  PubMed  Google Scholar 

  • Kraeber-Bodéré F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27:1487–1493

    Google Scholar 

  • Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL (2005) Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174:2186–2190

    Article  PubMed  Google Scholar 

  • Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28:623–630

    Article  CAS  PubMed  Google Scholar 

  • Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL, Scher HI (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596–1605

    Article  CAS  PubMed  Google Scholar 

  • Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev CD003506

    Google Scholar 

  • Nariculam J, Murphy DG, Jenner C, Sellars N, Gwyther S, Gordon SG, Swinn MJ (2009) Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol 82:571–576

    Article  CAS  PubMed  Google Scholar 

  • Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    Article  CAS  PubMed  Google Scholar 

  • Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643–648

    Article  PubMed  Google Scholar 

  • Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 34:1023–1030

    Google Scholar 

  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE (2015) COU-AA-302 Investigators Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160

    Article  CAS  PubMed  Google Scholar 

  • Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    Article  CAS  PubMed  Google Scholar 

  • Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ (2007) Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109:637–643

    Google Scholar 

  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    Article  PubMed Central  PubMed  Google Scholar 

  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197

    Article  CAS  PubMed  Google Scholar 

  • Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43:79–86

    Google Scholar 

  • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164

    Article  CAS  PubMed  Google Scholar 

  • Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41

    Google Scholar 

  • Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24:1868–1876

    Article  PubMed  Google Scholar 

  • Sweeney C, Chen YH, Carducci MA, Liu G, Jarrard DF, Eisenberger MA, Wong Y-N, Hahn NM, Kohli M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shevrin DH, Hussain M, Garcia JA, DiPaola RS (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s (suppl; abstr LBA2)

    Google Scholar 

  • Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM (2013) Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistent prostate cancer. Clin Cancer Res 19:5182–5891

    Google Scholar 

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  • Thomas DJ, Balaji VJ, Coptcoat MJ, Abercrombie GF (1992) Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial? J R Soc Med 85:318–319

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357:336–341

    Google Scholar 

  • Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G (1998) A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447–456

    Article  CAS  PubMed  Google Scholar 

Leitlinie

  • Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F (2008) European Association of Nuclear Medicine. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35:1934–1940

    Google Scholar 

  • Cookson MS, Lowrance WT, Murad MH, Kibel AS (2015) Castration-resistant prostate cancer: AUA guideline amendment. J Urol 193:491–499

    Article  PubMed  Google Scholar 

  • Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F (2013) Guidelines on prostate cancer. European Association of Urology, Arnhem

    Google Scholar 

  • Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen (S1). Deutsche Gesellschaft für Nuklearmedizin. http://www.nuklearmedizin.de/leistungen/leitlinien/html/radionuk_ther.php?navId=53 (zuletzt eingesehen am 06.05.2015 angemeldet unter AWMF-Registernummer: 031–029)

  • Wirth M, Weißbach L, Ackermann R, Alberti W, Albrecht C, Göckel-Beining B, Froehner M, Hinkelbein W, Miller K, Rübben H, Wiegel T, Wolff J, Wörmann B (2011) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Johannes Huber, Michael Fröhner & Manfred Wirth

  2. Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Claudia Brogsitter & Jörg Kotzerke

  3. Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Tobias Hölscher & Michael Baumann

  4. OncoRay – Nationales Zentrum für Strahlenforschung in der Onkologie, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Tobias Hölscher & Michael Baumann

Authors
  1. Johannes Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Brogsitter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg Kotzerke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tobias Hölscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Fröhner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manfred Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Huber .

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Universitätsmedizin Mannheim, Mannheim, Baden-Württemberg, Germany

    Maurice Stephan Michel

  2. Klinik für Urologie, Universitätsklinikum Mainz, Mainz, Germany

    Joachim W. Thüroff

  3. Klinik für Urologie, Universitätsklinikum Salzburg, Salzburg, Austria

    Günther Janetschek

  4. Klinik für Urologie, Universitätsklinikum Dresden, Dresden, Germany

    Manfred Wirth

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Huber, J. et al. (2015). Prostatakarzinom: palliative Therapie. In: Michel, M., Thüroff, J., Janetschek, G., Wirth, M. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41168-7_144-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-41168-7_144-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-41168-7

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Prostatakarzinom: palliative Therapie
    Published:
    26 November 2022

    DOI: https://doi.org/10.1007/978-3-642-41168-7_144-2

  2. Original

    Prostatakarzinom: palliative Therapie
    Published:
    29 April 2015

    DOI: https://doi.org/10.1007/978-3-642-41168-7_144-1

Search

Navigation